Winton Group LTD Dynavax Technologies Corp Transaction History

Winton Group LTD

$1.37 Billion
Q2 2024

A detailed history of Winton Group LTD transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Winton Group LTD holds 82,403 shares of DVAX stock, worth $931,153. This represents 0.07% of its overall portfolio holdings.

Number of Shares

82,403

Previous 75,378 9.32%

Holding current value

$931,153

Previous $935,000 1.07%

% of portfolio

0.07%

Previous 0.07%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$10.73 - $12.58 $75,378 - $88,374	7,025 Added 9.32%	82,403 $925,000
Q1 2024 May 14, 2024	BUY	$11.7 - $14.98 $486,965 - $623,482	41,621 Added 123.3%	75,378 $935,000
Q4 2023 Feb 12, 2024	SELL	$13.09 - $14.98 $15,708 - $17,976	-1,200 Reduced 3.43%	33,757 $471,000
Q3 2023 Nov 13, 2023	SELL	$12.64 - $14.99 $140,847 - $167,033	-11,143 Reduced 24.17%	34,957 $516,000
Q2 2023 Aug 14, 2023	SELL	$9.85 - $13.17 $641,077 - $857,156	-65,084 Reduced 58.54%	46,100 $595,000
Q1 2023 May 12, 2023	BUY	$9.44 - $11.88 $161,877 - $203,718	17,148 Added 18.24%	111,184 $1.09 Million
Q4 2022 Feb 14, 2023	BUY	$10.27 - $13.29 $118,556 - $153,419	11,544 Added 13.99%	94,036 $1 Million
Q3 2022 Nov 10, 2022	BUY	$9.93 - $17.44 $16,444 - $28,880	1,656 Added 2.05%	82,492 $861,000
Q2 2022 Aug 10, 2022	BUY	$7.45 - $12.83 $298,350 - $513,803	40,047 Added 98.18%	80,836 $1.02 Million
Q1 2022 May 11, 2022	BUY	$9.75 - $14.44 $59,426 - $88,011	6,095 Added 17.57%	40,789 $442,000
Q4 2021 Feb 10, 2022	BUY	$13.17 - $20.94 $456,919 - $726,492	34,694 New	34,694 $488,000
Q2 2018 Aug 20, 2018	SELL	$15.15 - $20.75 $151,787 - $207,894	-10,019 Closed	0 $0
Q1 2018 May 21, 2018	BUY	$14.65 - $19.9 $146,778 - $199,378	10,019 New	10,019 $0

Others Institutions Holding DVAX

# of Institutions

259

Shares Held

132M

Call Options Held

371K

Put Options Held

99.2K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.43B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.

Account